Trixona

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trixona

Property Description
Active Ingredient Ceftriaxone
Form Sterile powder for injection/infusion
Pharmacological Class Third-generation cephalosporin antibiotic
General Purpose Fighting serious systemic bacterial infections
Origin Semisynthetic

What Type of Antibiotic is Trixona (Ceftriaxone)?

Trixona is a medication containing the active ingredient Ceftriaxone, a powerful semisynthetic antibiotic primarily used to treat serious systemic bacterial infections. It is a key member of the third-generation cephalosporin class, which is a sophisticated and advanced subgroup of the broader beta -lactam antibiotics. The medicine is clinically recognized for its unique extended elimination half-life compared to other cephalosporins, a differentiating factor that often allows for once-daily administration in clinical settings.


Composition and Form: How is Trixona Prepared?

Trixona is a single-ingredient product supplied as the sterile compound Ceftriaxone sodium in a powder form within a vial. Since the drug is designed for parenteral administration (by injection or infusion), the sterile powder must be thoroughly mixed with a designated diluent, such as Water for Injection or a local anesthetic solution, to create the final liquid preparation. This form and required delivery method ensure that the full dose is rapidly introduced to the bloodstream, which is essential for achieving the high tissue and fluid concentrations required to treat severe infections like bacterial meningitis.


Trixona's General Purpose: What Does it Help to Do?

The general purpose of Trixona is the rapid and direct destruction of infectious bacteria throughout the body. It functions as a bactericidal agent, actively killing bacteria by disrupting the synthesis of their cell walls. This effective, destructive mechanism is crucial for quickly neutralizing severe systemic bacterial challenges. For example, its strong bactericidal action is often leveraged for prophylaxis (prevention) of infection in patients undergoing certain types of surgery, a common and well-established clinical application.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Trixona?

Possible side effects and safety information

The safety profile of Ceftriaxone (Trixona) is defined by officially documented adverse reactions and specific regulatory limitations, classified by government health authorities.


Adverse Reaction Scope

The frequency of adverse reactions is defined using standardized regulatory categories:

  • Common (1/100 to <1/10): Includes gastrointestinal effects such as diarrhea, skin reactions like rash, and temporary changes in blood components (e.g., eosinophilia, leukopenia), along with elevations in liver enzymes.
  • Uncommon (1/1,000 to <1/100): Less frequently reported effects include nausea, vomiting, headache, dizziness, and localized reactions like phlebitis (vein inflammation) at the injection site.

The official documents group effects by body system, including the Gastrointestinal, Blood and Lymphatic System, and Hepatobiliary Disorders.


Serious Adverse Reactions and Constraints

The regulatory labeling explicitly documents rare but clinically significant adverse events:

  • Serious Hypersensitivity: Severe systemic reactions, including anaphylactic shock and severe cutaneous adverse reactions (SCARs), have been reported.
  • Gastrointestinal Complications: The potential for Pseudomembranous Colitis (Clostridioides difficile-associated diarrhea), which may arise during or after treatment.
  • Unique Safety Restriction: Ceftriaxone must not be administered simultaneously with any calcium-containing intravenous solutions (including continuous infusions like parenteral nutrition) due to the documented risk of forming ceftriaxone-calcium precipitates.

Population-Specific Safety Notes

A key safety constraint applies to the Neonatal population: Ceftriaxone is contraindicated in premature infants and in jaundiced or acidotic full-term neonates due to a documented risk of bilirubin encephalopathy (kernicterus).


Connection to the overall safety profile:

This official safety information structures the understanding of risks by clearly separating frequently reported effects from critical but rare events like anaphylaxis. The profile's most significant constraint is the absolute prohibition against simultaneous co-administration with calcium-containing products in all age groups, a unique and critical safety delineation required by regulatory bodies.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Trixona (Ceftriaxone)

Property Official Regulatory Statement
Documented Overdose Presentations Overdose may present with nausea, vomiting, and diarrhoea. Serious neurological adverse reactions, including convulsions, myoclonia (myoclonic jerks), and encephalopathy (e.g., somnolence, confusion, or altered mental status), have been reported with high systemic concentrations.
Serious / Life-Threatening Outcomes Cases of fatal reactions involving Ceftriaxone-Calcium precipitates in the lungs and kidneys have occurred in neonates (less than 28 days of age) who received concurrent intravenous calcium-containing solutions.
Emergency Response Statements No specific antidote is known for Trixona overdose. Treatment is limited to symptomatic and supportive measures. Official labeling states that Ceftriaxone concentrations cannot be effectively reduced by haemodialysis or peritoneal dialysis.
When Immediate Medical Help is Required Seek immediate medical attention for suspected overdose. In the event of severe hypersensitivity reactions (which may mimic acute adverse events), treatment must be discontinued immediately, and adequate emergency measures must be initiated as mandated by regulatory documents.
Population-Specific Overdose Notes Neonates are at a higher risk of fatal precipitation events. Infants and small children have an increased risk of developing biliary precipitates or sludge at higher doses. Patients with combined severe renal and hepatic impairment require dosage adjustment to mitigate the risk of drug accumulation.

The official regulatory profile defines overdose by its acute systemic manifestations, including serious neurological effects, and the critical risk of precipitation in vulnerable populations like neonates. Immediate medical help is mandated for suspected overdose or severe reactions. Management is restricted to symptomatic support, given the lack of a specific antidote and the ineffectiveness of dialysis in reducing the drug's concentration.

Therapeutic Uses of Trixona

What Trixona Treats: Main Uses and Benefits

Trixona (Ceftriaxone) is commonly used to help manage severe bacterial infections and is considered relevant in managing conditions marked by heightened physiological stress. Its primary application is in situations where acute, intensive antimicrobial support is needed.

The medication is predominantly applied in clinical settings that involve acute or unstable symptom patterns, such as systemic infections like sepsis and bacterial meningitis, as well as complicated deep-tissue issues including bone and joint infections, pyelonephritis, and intra-abdominal infections. Furthermore, it is applied in addressing specific acute presentations like certain presentations of gonorrhea and is commonly used for infection prophylaxis during major surgery.

This supportive use is applied in addressing the symptom cluster of high, persistent fever, chills, and intense, localized pain. This assists with maintaining functional stability by helping to stabilize the physiological imbalance.

“The appropriate use of this medication may assist in easing the overall symptom burden associated with severe infection.”

The medication is relevant for easing symptoms related to inflammatory or irritative states, thereby supporting general well-being during symptomatic phases.

Quick Fact: Addressing Severe Pain
Trixona is relevant for easing symptoms related to inflammatory or irritative states, such as localized discomfort and pain associated with severe, deep-seated infections in areas like the bones and joints.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Trixona?

Eligibility for Trixona (Ceftriaxone) is defined by official regulatory documentation, focusing on patient age, prior allergies, and existing organ function.

Absolute Contraindications (Must Not Use):

Population Restriction Rationale (as documented)
Hypersensitivity Contraindicated in patients allergic to Ceftriaxone or any other cephalosporin antibiotic. Risk of severe allergic reaction [2.1].
Neonates (le 28 days) & IV Calcium Contraindicated if receiving or expected to receive intravenous calcium-containing solutions (e.g., TPN) [2.2]. Risk of precipitation in the lungs and kidneys [1.1].
Specific Neonates Contraindicated in premature neonates up to 41 weeks postmenstrual age, and in hyperbilirubinemic neonates [2.2]. Risk related to bilirubin displacement [1.1].

Conditional or Restricted Use:

  • Organ Impairment: Patients with both severe hepatic (liver) and severe renal (kidney) impairment should not receive more than 2 grams per day [1.5]. This is a regulatory-mandated maximum daily dose for this population.
  • Pregnancy Status: Use is permitted only if clearly needed, holding an FDA Category B status [4.2].
  • Older Adults: Generally eligible; no dose adjustment is necessary if their renal and hepatic functions are satisfactory [2.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Trixona (ceftriaxone) based on physical incompatibilities and pharmacodynamic effects, with no stated dependence on major cytochrome P450 enzyme metabolism. This structure mandates specific restrictions and prohibitions, particularly with co-administered intravenous solutions and in specific patient populations.

Classification Interacting Substance/Condition Restriction/Official Outcome
Contraindicated Combination IV Calcium Solutions (Neonates le 28 days) Co-administration is formally prohibited due to the documented risk of potentially fatal ceftriaxone-calcium salt precipitation in the organs.
Contraindicated Condition Hyperbilirubinemic Neonates Use is prohibited due to the risk of ceftriaxone displacing bilirubin from albumin binding, a documented effect.
Timing-Based Restriction IV Calcium Solutions (Patients > 28 days) Simultaneous administration is prohibited. Sequential administration is permitted only if the infusion lines are thoroughly flushed between administrations.
Exposure-Modifying Risk Vitamin K Antagonists (e.g., Warfarin) Official labeling states co-administration may alter prothrombin time, which is a documented risk of modifying the patient's coagulation status.
Pharmacodynamic Risk Aminoglycoside Antibacterials Combination is documented to increase the risk of specific organ toxicity, notably nephrotoxicity.
Population Note Hepatic and Renal Impairment (Combined) A restricted dose is noted in official documents for patients with significant impairment in both organs to mitigate accumulation.

Mechanism of Action

How Trixona Works: Mechanism of Action

Inhibition of Bacterial Cell Wall Synthesis

Trixona acts as a bactericidal inhibitor by selectively targeting and binding to specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs). This beta-lactam structure covalently attaches to the active site of transpeptidases, blocking their function. This inhibition prevents the final step in the synthesis of the bacterial peptidoglycan cell wall, specifically the necessary cross-linking of peptidoglycan strands. This targeted action is the initial event leading to structural compromise and ultimate cell death.

Cascade Leading to Osmotic Lysis

The resulting defective cell wall fails to counteract the high internal osmotic pressure of the bacteria. This structural failure triggers a mechanistic cascade leading to cell rupture (lysis). This direct cell killing results in the physiological consequence of a reduction in the population of susceptible organisms. This primary mechanism is constrained by bacterial counter-mechanisms, such as the production of beta-lactamase enzymes, which chemically inactivate the drug before it can bind to the PBPs, limiting the range of susceptible organisms.

Dosage and Administration Information

Administration Scope and Route

Trixona (Ceftriaxone) is an injectable medicine administered exclusively through the parenteral route, following official regulatory guidelines. It is supplied as a sterile powder that requires reconstitution with a specific diluent prior to use. The officially approved methods of delivery are Intravenous (IV) injection or infusion and Intramuscular (IM) injection.

Official Dosing and Frequency

The standardized administration pattern is typically once daily (q24hr) for most adult regimens, although the dose may be divided into twice-daily administration for amounts greater than 2 g.

Feature Instruction
Usual Daily Dose 1 g to 2 g for most adults.
Maximum Daily Dose 4 g.
Duration of Therapy Typically 4 to 14 days, or continuing for 48 to 72 hours after the patient is afebrile.

Preparation and Procedural Constraints

Preparation involves using Water for Injection for IV use. For IM injection, a 1% Lidocaine solution is typically utilized, and no more than 1 g should be injected per single site. A critical constraint in administration is the prohibition against simultaneous mixing or administration with any calcium-containing intravenous solutions due to the risk of precipitation. Furthermore, larger IV doses (greater than or equal to 2 g) must be infused over a minimum of 30 minutes to adhere to labeled administration conditions. Dosage adjustments are generally not required for older adults or in cases of minor renal or hepatic impairment up to 2 g daily.

Recent Clinical Evidence

Research evidence / Overview of studies for Trixona

Evidence for Use in Severe Systemic Infections: Bacterial Meningitis

Research exploring Trixona for conditions such as bacterial meningitis primarily consists of comparative trials, including short-term randomized controlled studies. These studies were designed to monitor the activity of Trixona alongside alternative treatments. Research examined critical outcomes related to systemic or functional imbalance, specifically looking at how the drug penetrated the cerebrospinal fluid (CSF) and the time required for microbiological clearance of the infection. Study populations included infants, pediatric patients, and adults, often in research settings involving fluctuating or unstable symptoms.

Studies monitored how symptoms evolved in the observed populations and documented the time required to achieve microbiological clearance among participants. Research highlights changes measured during the study period, reporting patterns observed in 30-day outcomes, which included mortality outcomes and the frequency of certain adverse neurological events. Despite these observations, the evidence is limited regarding long-term outcomes related to neurocognitive function or persistent neurological consequences following treatment. Follow-up durations were limited in many trials, meaning the persistence of the drug’s effect beyond the immediate observation period is not fully established.


Evidence for Use in Complicated Organ Infections: Urinary Tract Infections

Research exploring Trixona for use in conditions such as complicated infections like pyelonephritis involved short-term randomized controlled trials and observational studies focusing on hospitalized adult patients. Studies monitored outcomes related to physical discomfort and systemic stability, tracking endpoints such as the time needed for patients to achieve stability and rates of microbiological eradication. Findings describe group patterns related to hospital discharge rates among the studied populations.

Comparative evidence is lacking when assessing Trixona against every single alternative oral and intravenous therapy currently available for complicated UTIs. In addition, there is limited information for long-term outcomes, as monitoring for infection recurrence or re-infection is not consistently documented beyond the acute trials. Evidence quality varies across studies, and data for patients with rare or complex urological anatomies remain insufficient.


Evidence for Use in Prevention: Surgical Prophylaxis

The evidence base exploring the use of Trixona for preventing infections in patients undergoing surgical procedures is founded on systematic reviews and meta-analyses, which aggregate data from numerous randomized controlled trials (RCTs). Research examined outcomes linked to inflammatory or irritative states, focusing specifically on monitoring the incidence of Surgical Site Infection (SSI) in the first 30 days after surgery.

Systematic reviews aggregated data and reported measurements of SSI rates for various patient cohorts. Research is still ongoing to clarify the optimal timing and administration approach across the highly diverse array of surgical procedures. The follow-up durations were typically limited to 30 days, meaning there is limited information for long-term outcomes related to potential delayed infections.

Key Studies & References

  1. MedlinePlus Drug Information: Ceftriaxone

Frequently Asked Questions (FAQ)

Common questions about Trixona (FAQ)

Q: Is Trixona the same type of medicine as [similar drug name]?

A: Trixona's active ingredient, Ceftriaxone, belongs to the third-generation cephalosporin class of antibiotics. This class represents a sophisticated subgroup of the larger beta-Lactam medicines, distinguishing it as a specific type of antibiotic used for susceptible infections.


Q: How long after starting Trixona should I expect to see its full effect?

A: The duration of treatment is generally guided by the type and severity of the infection. Official prescribing information states that treatment is generally continued for a total duration of 4 to 14 days, and for a minimum of two days after the signs and symptoms of the infection have disappeared.


Q: Can Trixona interact with herbal remedies?

A: Official interaction lists focus on prescription drugs, over-the-counter medications, and certain vitamins. Specific information on every possible herbal remedy is not typically documented in official regulatory labeling. Information regarding all supplements and herbal remedies can be reviewed with a healthcare professional.


Q: What does the research evidence actually say about Trixona's effectiveness?

A: Studies and official information indicate Trixona's use in serious systemic infections, including conditions like bacterial meningitis, complicated urinary tract infections, and for surgical prophylaxis (prevention). Research focuses on measured outcomes such as rates of microbiological clearance (reducing the presence of susceptible organisms) and infection incidence rates in studied populations.


Q: Is Trixona appropriate for children or adolescents?

A: Use in children and adolescents is described in official documents, where dosage is adjusted based on the patient's weight and age. The absolute prohibitions against use are specifically reserved for neonates (less than 28 days old) and those with specific pre-existing conditions like hyperbilirubinemia (excessive bilirubin).


Q: Is Trixona available over-the-counter?

A: No. Official labeling classifies Trixona as a Human Prescription Drug and is administered by injection or infusion. Due to its intended use and required method of delivery, it is not available for purchase over-the-counter.


Q: What should I look for in the Patient Information Leaflet (PIL) for Trixona?

A: Official patient leaflets (PILs/Med Guides) are designed to emphasize key safety constraints. You can expect to find information highlighting the absolute prohibition of simultaneous co-administration with calcium-containing solutions, details on serious adverse reactions, and the correct storage procedures for the drug.


Q: What happens if I stop taking Trixona suddenly?

A: Official labeling describes that immediate discontinuation is required in the event of severe hypersensitivity reactions (severe allergic responses). However, for other responses, such as the Jarisch-Herxheimer reaction, official documents state that antibiotic treatment should not be discontinued.


Q: Is it common to feel tired when starting Trixona?

A: Unusual tiredness or weakness is an effect described in official safety information. This is generally listed as a more common side effect in the official adverse reaction summaries.


Q: Can Trixona affect my ability to drive?

A: The drug's safety profile includes reports of dizziness and rare, serious neurological adverse reactions such as somnolence (drowsiness) or confusion. Official documents note these effects may potentially influence the ability to drive or operate machinery.


Q: Is Trixona considered safe for long-term use?

A: The typical duration of use is generally guided by the specific infection being treated, usually ranging from 4 to 14 days for most infections. Longer durations are noted in prescribing information for specific, severe conditions, such as endocarditis.


Q: Are there any common foods or drinks to avoid while on Trixona?

A: Official labeling does not typically describe restrictions regarding specific common foods or non-alcoholic beverages. The primary critical restriction involves intravenous calcium-containing solutions, which must not be given simultaneously with Trixona.


Q: Is Trixona addictive or habit-forming?

A: Trixona is not classified by the DEA (Drug Enforcement Administration) as a controlled substance. It is not listed in regulatory documents as an addictive or habit-forming drug.


Q: What should I do if I miss a dose of Trixona?

A: Since the medicine is administered on a fixed, professional schedule (by injection or infusion), patient information suggests that the healthcare professional who administers the medicine should be contacted if a scheduled dose is missed.


Q: Why does the official document list so many potential side effects for Trixona?

A: This practice is mandated by regulatory requirements. Agencies require all observed or reported adverse reactions from both clinical trials and post-marketing surveillance to be included in the official safety profile, regardless of how rarely they occur, to fully inform healthcare providers and patients.


Q: Are there any mental or mood changes associated with Trixona use?

A: Rare, serious neurological adverse reactions have been reported in post-marketing surveillance. These can include disturbances of consciousness such as confusion and somnolence (drowsiness).


Q: Do I need regular blood tests while taking Trixona?

A: Monitoring may be required for specific parameters, such as a complete blood count (CBC) and coagulation status (blood clotting time). This is often necessary for patients with co-existing liver or kidney conditions or those on concurrent medications.


Q: Can Trixona affect sleep?

A: Somnolence (drowsiness) is described in the safety information as a component of a possible, though rare, neurological adverse reaction. Patients can be aware of this potential effect.


Q: Are there any warnings about Trixona and sun exposure?

A: Official labeling does not generally associate Trixona with an increased risk of photosensitivity (unusual sun sensitivity) unlike some other classes of antibiotics.


Q: Is it safe to get vaccinated while taking Trixona?

A: Official documents note a specific interaction with the live cholera vaccine. The general applicability to all other vaccines is not explicitly stated in regulatory warnings.


Q: Does Trixona have a black box warning?

A: The most critical safety warnings, including the absolute prohibition of mixing or simultaneous administration with calcium-containing intravenous solutions, are prominently featured in the official prescribing information.


Q: Can Trixona be used in conjunction with other treatments for [condition]?

A: Official documents specify several antimicrobial medicines (like aminoglycosides) that may present an increased risk of toxicity when combined with Trixona, and others that are physically incompatible and must not be mixed. Any combination regimen is typically reviewed by a healthcare professional.


Q: Does Trixona interact with common cold or flu medicines?

A: Official interaction lists include common non-prescription medicines such as acetaminophen (Tylenol/Paracetamol) and some antihistamines. The full product label defines specific restrictions on concurrent use with other listed drugs.

How should Trixona be stored and disposed of?

The storage and disposal instructions for Trixona (ceftriaxone for injection) are defined by strict regulatory requirements to maintain product stability and ensure safe handling.

Official Storage Conditions

Condition Requirement
Powder Temperature Store the sterile powder at Controlled Room Temperature (20 C to 25 C).
Light Protection The dry powder must be protected from light and kept in the original container.
Solution Stability (Refrigerated) The reconstituted solution is typically stable for up to 10 days when refrigerated ( 2 C to 8 C).
Solution Stability (Room Temp) Reconstituted solution is typically stable for 48 hours at room temperature ( 15 C to 25 C).

Handling and Disposal Rules

  • The medicine must be stored out of the sight and reach of children.
  • Trixona must not be mixed or administered simultaneously with any solutions containing calcium.
  • Unused or expired product must not be discarded into household waste or wastewater.
  • Used needles and syringes must be disposed of in a designated puncture-proof sharps container according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trixona found in:

A-Z Index: